The anti-cytotoxic T-lymphocyte- associated protein 4 (CTLA-4) monoclonal antibody (mAb) ipilimumab is associated with hypophysitis in a dose-dependent manner, with rates up to 21% in patients with melanoma treated with a dose of 9 mg/kg [2]. The gene discussed is CTLA4; the disease is melanoma.